Korean pharmaceutical and biotech companies are using various open innovation tools to raise competitiveness in new drug development in the global market.In the past, Korean drugmakers conducted research in secrecy due to the risk of technology leakage. But now, they actively get technologies and bu
It is difficult to treat rare and intractable diseases because causes and treatment methods remain unclear. However, new therapeutics are emerging one after another to fight these diseases.So far, treatments for rare and intractable diseases have aimed to slow the disease progression or relieve symp
The government selected Humedix’s “polynucleotide sodium” (PN) technology as a national research project that will enhance Korea’s technological power, Humedix said.The Ministry of Trade, Industry and Energy picked Humedix’s “medical PN-based production technology with an average molecular weight of
Shares of CHA Vaccine Institute rose sharply on Monday, pushed up by news reports of global acute child hepatitis cases.The institute’s stock price jumped 24.65 percent to close at 8,640 won ($6.99) on Monday, and the price once shot up to the daily limit of 9,000 won during the intraday trading.The
Korean biotech and pharmaceutical companies are actively developing Alzheimer’s disease treatments in various forms, such as stem cell therapy and peptide drug.Korea Biotech Industry Organization (Korea BIO) published a report on the analysis of Alzheimer’s disease and the treatment development tren
Korean biotech companies are gearing up to promote their latest anticancer pipelines at the 2022 American Society of Clinical Oncology conference (ASCO 2022), which starts this week.ASCO 2022, the world’s largest annual cancer meet, will be in Chicago from June 3-7. Every year, mover than 40,000 sci
Shaperon, a clinical-stage biotech firm, said it passed the financial regulator’s preliminary review for initial public offering (IPO) on the Kosdaq market.The company said it aimed to go public in the second half of this year.The Korea Exchange (KRX) said Shaperon passed the preliminary review on T
Medipost said it would establish a subsidiary specializing in CDMO (contract development and manufacturing organization) business in cell and gene therapy.In a public filing on Tuesday, Medipost said it would change the investment method for CDMO in North America. Earlier, Medipost had said that it
Genexine, a Korean biotech firm, said it would deliver a corporate presentation at the upcoming H.C. Wainwright Global Investment Conference in the U.S.H.C. Wainwright, a U.S. investment bank, invites promising companies and holds a conference for investors twice a year.The investment conference wil
Bixink Therapeutics is accelerating efforts to build a diverse digital therapeutics (DTx) portfolio by clinching a series of DTx deals. Bixink is a biotech subsidiary of KPS Corp.On Tuesday, Bixink said it signed an agreement with LimbixHealth, a U.S. company, for the exclusive local development and
MedPacto said it would drop a phase 2 trial of vactosertib, an anti-cancer drug candidate, in desmoid tumors because it decided to focus vactosertib development on other types of cancer.In a public filing on Monday, the Kosdaq-listed biotech firm said it would voluntarily withdraw its local phase 2
Prestige BioPharma’s recent failure to get European approval for its Herceptin biosimilar could have resulted from the company’s changes in the manufacturing of the biosimilar during a phase-3 trial, the company said.The manufacturing change was due to the “product drift” of the original drug Hercep
Prestige BioPharma, a Singapore-based company, listed on the Kospi market, said it failed to get marketing approval for its Herceptin biosimilar product in Europe. The company’s stock price tanked immediately after the announcement.In a public disclosure on Friday, Prestige BioPharma said it receive
Celltrion said that it has completed the preliminary work for launching CT-P16, an Avastin (Ingredient: bevacizumab) biosimilar, after signing a global patent agreement for the biosimilar product with Genentech, the original developer of Avastin.Celltrion has conducted global patent agreements with
The global recognition of Korea’s bio-health industry and related products increased significantly in the wake of the Covid-19 pandemic, a survey showed.The Korea Health Industry Development Institute (KHIDI) released the results of the 2021 international survey on the brand recognition of Korean bi
Celltrion said it has submitted a global phase 3 clinical trial plan for CT-P47, a biosimilar for rheumatoid arthritis treatment Actemra (ingredient: tocilizumab), to Poland's drug agency, the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products.Celltrion started the
Samsung Bioepis received marketing approval for Amelivu Inj. (ranibizumab), a biosimilar referencing Lucentis to treat various eye diseases in Korea.However, the local market release of the treatment will take some time due to a patent-related agreement between Samsung Bioepis and Genentech, the dev
As cloud-based medical software products such as AI-based diagnostic assistance solutions are rapidly growing, medical institutions need new criteria for patient data management to reduce confusion, an expert said.Lim Joon-seok, head of the Digital Health Division of Yonsei University Health System,
Korean biotech companies said they would gather at Bio Korea 2022, a health and pharmaceutical industry trade fair, to discuss business strategies in the post-Covid-19 era.The Korea Health Industry Development Institute (KHIDI) and North Chungcheong Province jointly organized the annual event, which
Celltrion Healthcare said that it would expand direct sales, previously limited to only some products, to all products in the European market.The company has sold Remsima (ingredient: infliximab), a biosimilar for treating autoimmune diseases, directly in Europe since 2019. Since then, despite inten